The future direction of the US Department of Health & Human Services (HHS) under Robert F. Kennedy, Jr. was a worry for many pharmaceutical executives at the J.P. Morgan Healthcare Conference. Vaccine manufacturers, in particular, are preparing to push back against a wave of disinformation about the safety and efficacy of vaccines, given that Kennedy has espoused anti-vaccine rhetoric in the past.
Vaccine Manufacturers Prepare To Fight Disinformation With Transparency
At J.P. Morgan, GSK, Sanofi and Pfizer said they are prepared to address questions about vaccines under a new US administration, while former FDA commissioner Gottlieb warned of threats to public safety.
More from J.P. Morgan
More from Therapy Areas
• By
The obesity market leader has unveiled its second deal in days, paying $75m upfront for a potential first-in-class ACSL5 inhibitor, while the deal also provides some respite for Lexicon.
• By
The biotech is banking on itolizumab’s longer-term efficacy as well as unmet need in frontline acute graft-versus-host disease as it prepares to meet with the FDA.
• By
The company is planning to launch oxylanthanum carbonate for chronic kidney disease patients on dialysis with hyperphosphatemia.